secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0001628280-25-010245
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen FY2024 net loss $0.20; advances three gene therapy programs toward BLA filings
--------------------------------------------------------------------------------

- Q4 net loss $0.05/share; full-year net loss $0.20/share vs $0.26 in 2023.
- Cash $58.8M as of Dec 31, 2024; runway into Q1 2026; $65M financing secured in H2 2024.
- OCU400 Phase 3 RP enrollment on track for H1 2025; BLA/MAA target mid-2026.
- OCU410ST Stargardt Phase 2/3 pivotal trial FDA-aligned; BLA target 2027.
- OCU410 GA completed Phase 2 dosing; no serious adverse events; BLA target 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/0001628280-25-010245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025010245/ocgn-20250305.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-010245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer